In a study by Radzina et al., it was found that mpMRI had superior results compared to PSMA PET in the detection of local prostate cancer recurrence with sensitivity, specificity, PPV, and NPV values of 90.9%, 94.7%, 90.9%, and 94.7% vs. 94.7%, 63.6%, 77.8%, 58.3%, and 77.8%, respectively. This evidence concerns the gene FOLH1 and prostate carcinoma.